Benign prostatic hyperplasia (BPH) is a histopathological diagnosis characterized by epithelial cell & smooth muscle cell proliferation in the transition zone of the prostate leading to a non-malignant enlargement of the gland, which may result in lower urinary tract symptoms, including voiding and storage symptoms.
It is commonly called enlarged prostate.
Etiology is unknown but due to its similarity to the embryonic morphogenesis of the prostate has led to the hypothesis that BPH may be the result of "reawakening" in adulthood of embryonic induction processes.
Mirabegron appears to be a safe add-on therapy in men receiving tamsulosin for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia, according to data from the phase IV PLUS study.
Day temperature difference appears to influence lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH), such that the greater the difference, the worse the LUTS symptoms are and the higher the tendency to visit the emergency room is, a study reports.
The minimally invasive water vapour thermal therapy significantly reduced symptoms of benign prostatic hyperplasia (BPH), including lower urinary tract symptoms (LUTS) and urinary flow rate, and the improvements were sustained through to 5 years, according to long-term data released during the American Urological Association (AUA) 2020 Virtual Meeting.
Aquablation performs as well as transurethral resection of prostate (TURP) in terms of safety and efficacy for treating benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS), although the former is associated with a lower rate of retrograde ejaculation, according to the results of a systematic review.
The minimally invasive water vapour thermal therapy represents a viable approach for thermal ablative reduction of benign prostate hyperplasia (BPH), providing urinary symptom relief and quality of life improvement that are sustained over 4 years, a study has shown.
The selective α1A-adrenoceptor antagonist silodosin appears to safely and effectively reduce nocturia episodes in patients with benign prostatic hyperplasia (BPH), according to the results of an open-label trial.
The use of Aquablation in surgical prostate resection provides noninferior relief from benign prostate hyperplasia (BPH)-related lower urinary tract symptoms while reducing the risk of sexual dysfunction as compared with transurethral resection of the prostate (TURP), according to data from the WATER study.
The minimally invasive convective radiofrequency (RF) thermal therapy appears to provide early and durable relief of lower urinary tract symptoms in patients with benign prostatic hyperplasia (BPH), according to a team of US-based researchers. In addition, the procedure allows preservation of sexual function and can be performed on the median lobe and hyperplastic central zone tissue.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.